Details of the Drug Combination

General Information of Drug Combination (ID: DCYEMJG)

Drug Combination Name
Fedratinib BMS-986158
Indication
Disease Entry Status REF
Myelofibrosis Phase 1 [1]
Component Drugs Fedratinib   DM4ZBK6 BMS-986158   DM6LDI4
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Fedratinib
Disease Entry ICD 11 Status REF
Myelofibrosis 2A20.2 Approved [2]
Polycythemia vera 2A20.4 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Fedratinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [2]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Fedratinib Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Decreases Expression [7]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [6]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [6]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Increases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of BMS-986158
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
BMS-986158 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bromodomain and extraterminal domain protein (BET) TTE4BSY NOUNIPROTAC Inhibitor [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04817007) A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 212327
4 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
5 ClinicalTrials.gov (NCT02419417) Study of BMS-986158 in Subjects With Select Advanced Cancers (BET). U.S. National Institutes of Health.
6 Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. Eur J Pharmacol. 2015 Oct 15;765:188-97. doi: 10.1016/j.ejphar.2015.08.037. Epub 2015 Aug 20.
7 The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. J Biol Chem. 2022 Feb;298(2):101531. doi: 10.1016/j.jbc.2021.101531. Epub 2021 Dec 23.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)